Achilles Therapeutics plc
achillestx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Apr 4, 2024. Its latest SEC filing is a 15-12G from Mar 21, 2025.
20-F for FY2023, filed Apr 4, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Developed precision T cell therapies for solid tumors, using patient tumor samples to identify targets and manufacture treatment candidates from patients’ cells.
20-F for FY2023, filed Apr 4, 2024We are a clinical stage immuno-oncology biopharmaceutical company developing precision T cell therapies to treat multiple types of solid…View ↗
The foundation of our approach is the PELEUS AI-powered platform which is designed to identify each patient’s tumor-specific clonal…View ↗
To create our cNeT product candidates, we first procure tumor tissue and blood samples from the patient. We then extract, sequence and…View ↗
How Did They Make Money?
No revenue was reported.
20-F for FY2023, filed Apr 4, 2024
Who Did They Compete With?
Competes with Kite Pharma, Iovance, Adaptimmune Therapeutics, Autolus, Instil Bio, Neogene Therapeutics, BioNTech, Turnstone Biologics, Immatics, Obsidian Therapeutics, and KSQ Therapeutics
20-F for FY2023, filed Apr 4, 2024Advanced T cell therapies are under evaluation in solid tumors by multiple biotechnology and pharmaceutical companies, including Kite…View ↗
Loading...
